Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Retained Earnings: 2009-2024

Historic Retained Earnings for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to -$100.3 million.

  • Ani Pharmaceuticals' Retained Earnings rose 43.54% to -$50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.6 million, marking a year-over-year increase of 43.54%. This contributed to the annual value of -$100.3 million for FY2024, which is 25.14% down from last year.
  • As of FY2024, Ani Pharmaceuticals' Retained Earnings stood at -$100.3 million, which was down 25.14% from -$80.1 million recorded in FY2023.
  • Ani Pharmaceuticals' Retained Earnings' 5-year high stood at -$11.4 million during FY2020, with a 5-year trough of -$100.3 million in FY2024.
  • For the 3-year period, Ani Pharmaceuticals' Retained Earnings averaged around -$92.6 million, with its median value being -$97.3 million (2022).
  • In the last 5 years, Ani Pharmaceuticals' Retained Earnings plummeted by 317.64% in 2021 and then climbed by 17.63% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Retained Earnings (Yearly) stood at -$11.4 million in 2020, then crashed by 317.64% to -$47.8 million in 2021, then plummeted by 103.68% to -$97.3 million in 2022, then grew by 17.63% to -$80.1 million in 2023, then declined by 25.14% to -$100.3 million in 2024.